IMMUNOTHERAPY OF CANCER USING CYTOKINE GENE-MODIFIED TUMOR VACCINES

被引:0
|
作者
GILBOA, E [1 ]
LYERLY, HK [1 ]
VIEWEG, J [1 ]
SAITO, S [1 ]
机构
[1] MEM SLOAN KETTERING CANC CTR, DEPT SURG, UROL SERV, NEW YORK, NY 10021 USA
关键词
GENE THERAPY; IMMUNOTHERAPY; TUMOR VACCINES; CYTOKINE;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Distant metastasis is the major cause for therapeutic failures in clinical oncology. Active immunotherapy of patients with low tumor burden would not only contribute to further reduction of the remaining tumor burden to subclinical levels, but it would also establish a constant state of immunity, i.e. immunological memory, that could protect the patient from recurrence of disease. Studies employing rodent tumor models with little or no intrinsic immunogenicity have shown that genitically modified tumor cell preparations consisting of irradiated tumor cells transduced with and expressing cytokines such as IL-2, IL-6, IFN-gamma or GM-CSF were capable of inducing the regression of a preexisting tumor burden and cure animals from their disease. Moreover, in some instances the cured animals have retained immunological memory, as indicated by the fact that such animals have resisted a second challenge with the parental tumor cells. Induction of potent immune responses in tumor bearing animals against nonimmunogenic tumors supports the view that active immunization of Cancer patients deserves consideration despite lack of demonstrable immunogenicity in many human tumors.
引用
收藏
页码:409 / 417
页数:9
相关论文
共 50 条
  • [31] GENE-MODIFIED LEUKOCYTES FOR CANCER THERAPY
    Pegram, Hollie J.
    Xu, Yuekang
    Moeller, Maria
    Westwood, Jennifer A.
    Smyth, Mark J.
    Darcy, Phillip K.
    Kershaw, Michael H.
    JOURNAL OF GENE MEDICINE, 2009, 11 (09): : 844 - 844
  • [32] GENE-MODIFIED CELLS FOR THE TREATMENT OF CANCER
    WHARTENBY, KA
    ABRAHAM, GN
    CALABRESI, PA
    ABBOUD, CN
    CALABRESI, P
    MARROGI, A
    FREEMAN, SM
    PHARMACOLOGY & THERAPEUTICS, 1995, 66 (01) : 175 - 190
  • [33] Gene-Modified Cellular Vaccines: Technologic Aspects and Clinical Problems
    Mackiewicz, J.
    Mackiewicz, A.
    TRANSPLANTATION PROCEEDINGS, 2010, 42 (08) : 3287 - 3292
  • [34] Immunological therapy of human tumors by gene-modified cellular vaccines
    Parmiani, G
    FOLIA BIOLOGICA, 2000, 46 (06) : 207 - 209
  • [35] IMMUNOTHERAPY OF SPONTANEOUS METASTATIC LUNG CANCER WITH TUMOR ANTIGEN-PULSED, INTERLEUKIN-12 GENE-MODIFIED DENDRITIC CELLS
    陈吉泉
    修清玉
    颜泽敏
    罗文侗
    ChineseJournalofCancerResearch, 2003, (03) : 29 - 35
  • [36] THE USE OF GENE-MODIFIED TUMOR-INFILTRATING LYMPHOCYTES FOR CANCER-THERAPY
    HWU, P
    ROSENBERG, SA
    GENE THERAPY FOR NEOPLASTIC DISEASES, 1994, 716 : 188 - 199
  • [37] Adoptive transfer of chimeric FcεRI gene-modified human T cells for cancer immunotherapy
    Teng, Michele W. L.
    Kershaw, Michael H.
    Jackson, Jacob T.
    Smyth, Mark J.
    Darcy, Phillip K.
    HUMAN GENE THERAPY, 2006, 17 (11) : 1134 - 1143
  • [38] Investigation of the role of gene-modified CD4+ T cell subsets for cancer immunotherapy
    Darcy, Phillip
    Moeller, Maria
    Trapani, Joseph
    Smyth, Mark
    Kershaw, Michael
    HUMAN GENE THERAPY, 2008, 19 (10) : 1138 - 1138
  • [39] AN ANTICANCER DRUG DELIVERY APPROACH USING GENE-MODIFIED TUMOR-CELLS
    FREEMAN, SM
    WHARTENBY, KA
    ABBOUD, CN
    MOOLTEN, FL
    KOEPLIN, DS
    ABRAHAM, GN
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 249 - 249
  • [40] Bria-OTS immunotherapy platform: Harnessing gene-modified tumor cells to reinvigorate the cancer immunity cycle for precision anti-tumor responses
    Lopez-Lago, Miguel A.
    Bhardwaj, Vikas
    Kesarwani, Pravin
    Zheng, Xiaoyi
    Pachhal, Sagarika
    Cournoo, Patience
    Cortez, Renee
    Wiseman, Charles L.
    Williams, William V.
    CANCER RESEARCH, 2024, 84 (06)